Thrombin generation in Cushing's Syndrome: Do the conventional clotting indices tell the whole truth?

Pituitary

Volumn 17, Issue 1, 2014, Pages 68-75

  Koutroumpi, S ^a   Spiezia, L ^b   Albiger, N ^a   Barbot, M ^a   Bon, M ^b   Maggiolo, S ^b   Gavasso, S ^b   Simioni, P ^b   Frigo, A ^b   Mantero, F ^a   Scaroni, C ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

Author keywords

Cushing's Syndrome; Metabolic Syndrome; Prothrombotic state; Thrombin generation

Indexed keywords

ADULT; AGED; AGED, 80 AND OVER; BLOOD COAGULATION; BLOOD COAGULATION TESTS; CUSHING SYNDROME; DIABETES COMPLICATIONS; DYSLIPIDEMIAS; FEMALE; HUMANS; HYDROCORTISONE; HYPERTENSION; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; THROMBIN;

EID: 84895075748     PISSN: 1386341X     EISSN: 15737403     Source Type: Journal    
DOI: 10.1007/s11102-013-0467-3     Document Type: Article

References (38)

1. Arnaldi G, Agneli A, Atkinson AB, Bertagna X, Cavagnini F, Chrousos GP, Fava GA, Findling JW, Gaillard RC, Grossman AB, Kola B, Lacroix A, Mancini T, Mantero F, Newell-Price J, Nieman LK, Sonino N, Vance ML, Giustina A, Boscaro M (2003) Diagnosis and complications of Cushing's Syndrome: a consensus statement. J Clin Endocrinol Metab 88:5593-5602
2. Extabe J, Vasquez JA (1994) Morbidity and mortality in Cushing's disease: an epidemiological approach. Clin Endocrinol 40:479-484
3. Lindholm J, Juul S, Jorgensen JOL, Astrup J, Bjerre P, Feldt Rasmussen U, Hagen C, Jorgensen J, Kosteljanetz M, Kristensen LO, Laurberg P, Schmidt K, Weeke J (2001) Incidence and late prognosis of Cushing's Syndrome: a population based study. J Clin Endocrinol Metab 86:117-123
4. Dekkers OM, Biermasz NR, Pereira AM, Roelfsema F, Van Aken MO, Voormolen JHC, Romijn JA (2007) Mortality in patients treated for Cushing's disease is increased compared with patients treated for nonfunctioning pituitary macroadenoma. J Clin Endocrinol Metab 92:976-981
5. Colao A, Pivonello R, Spiezia S, Faggiano A, Ferone D, Filippella M, Marzullo P, Cerbone G, Siciliani M, Lombardi G (1999) Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure. J Clin Endocrinol Metab 84:2664-2672
6. Clayton RN, Raskauskiene D, Reulen RC, Jones PW (2011) Mortality and morbidity in Cushing's disease over 50 years in Stoke-on-Trent, UK. J Clin Endocrinol Metab 96:632-642
7. Bolland MJ, Holdaway IM, Berkeley JE, Lim S, Dransfield WJ, Conaglen JV, Croxson MS, Gamble GD, Hunt PJ, Toomath RJ (2011) Mortality and morbidity in Cushing's Syndrome in New Zealand. Clin Endocrinol 75:436-442
8. Miljic P, Miljic D, Cain JW, Korbonits M, Popovic V (2012) Pathogenesis of vascular complications in Cushing's Syndrome. Review. Hormones 11:21-30
9. Manetti L, Bogazzi F, Giovannetti C, Raffaelli V, Genovesi M, Pellegrini G, Ruocco L, Iannelli A, Martino E (2010) Changes of coagulation indexes and occurrence of venous thromboembolism in patients with Cushing's Syndrome: results from a retrospective study before and after surgery. Euro J Endocrinol 163:783-791
10. Fatti LM, Bottasso B, Invitti C, Coppola R, Cavanigni F, Mannucci PM (2000) Markers of activation of coagulation and fibrinolysis in patients with Cushing's Syndrome. J Endocrinol Invest 23:145-150
11. Hemker HC, Beguin S (1995) Thrombin generation in plasma: its assessment via the endogenous thrombin potential. Thromb Haemost 74:134-138
12. Kyrle PA, Mannhalter C, Béguin S, Stumpflen A, Hirschl M, Weltermann A, Stain M, Brenner B, Pabinger K, Eichinger S (1998) Clinical studies and thrombin generation in patients homozygous or heterozygous for the G20210A mutation in the prothrombin gene. Arterioscl Thromb Vasc Biol 18:1287-1291
13. Siegemund T, Petros S, Siegemund A, Scholz U, Engelmann L (2003) Thrombin generation in severe haemophilia A and B: the endogenous thrombin potential in platelet-rich plasma. Thromb Haemost 90:781-786
14. Kakkar VV, Hoppenstead DA, Fareed J, Kadziola Z, Scully M, Nakov R, Breddin HK (2002) Randomized trial of different regimens of heparins and in vivo thrombin generation in acute deep vein thrombosis. Blood 99:1965-1970
15. Ay L, Kopp HP, Brix JM, Ay C, Quehenberger P, Schernthaner GH, Pabinger I, Schernthaner G (2010) Thrombin generation in morbid obesity: significant reduction after weight loss. J Thromb Haemost 8:759-765
16. Casonato A, Pontara E, Sartorello F, Cattini MG, Sartori MT, Padrini R, Girolami A (2002) Reduced von Willebrand factor survival in type vicenza von Willebrand disease. Blood 99:180-184
17. Sartori MT, Danesin C, Saggiorato G, Tormene D, Simioni P, Spiezia L, Patrassi GM, Girolami A (2003) The PAI-I gene 4G/5G polymorphism and deep vein thrombosis in patients with inherited thrombophilia. Clin Appl Thromb Hemost 9:299-307
18. Simioni P (1999) The molecular genetics of familial venous thrombosis. Baillieres Best Pract Res Clin Haematol 12:479-503
19. Rossetto V, Spiezia L, Franz F, Salmaso L, Pozza LV, Gavasso S, Simioni P (2009) The role of antiphospholipid antibodies toward the protein C/protein S system in venous thromboembolic disease. Am J Hematol 84:594-596
20. Stuijver DJF, Van Zaane B, Feelders RA, Debeij J, Cannegieter SC, Hermus AR, Van den Berg G, Pereira AM, De Herder WW, Wagenmakers MA, Kerstens MN, Zelissen PM, Fliers E, Schaper N, Drent ML, Dekkers OM, Gerdes VE (2011) Incidence of venous thromboembolism in patients with Cushing's Syndrome: a multicenter cohort study. J Clin Endocrinol Metab 96:3525-3532
21. Fritsch P, Kleber M, Rosenkranz A, Fritsch M, Muntean W, Mangge H, Reinehr T (2010) Haemostatic alterations in overweight children: associations between Metabolic Syndrome, thrombin generation, and fibrinogen levels. Atherosclerosis 212:650-655
22. Ay L, Hoellerl F, Ay C, Brix JM, Koder S, Schernthaner GH, Pabinger I, Schernthaner G (2012) Thrombin generation in type 2 diabetes with albuminuria and macrovascular disease. Euro J Clin Invest 42:470-477
23. Tripodi A, Branchi A, Chantarangkul V, Clerici M, Merati G, Artoni A, Mannucci PM (2011) Hypercoagulability in patients with type 2 diabetes mellitus detected by a thrombin generation assay. J Thromb Thrombolysis 31:165-172
24. Erem C, Nuhoglu I, Yilmaz M, Kocak M, Demirel A, Ucuncu O, Onder Ersoz H (2009) Blood coagulation and fibrinolysis in patients with Cushing's Syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor and unchanged thrombin-activatable fibrinolysis inhibitor levels. J Endocrinol Invest 32:169-174
25. Van der Pas R, De Bruin C, Leebeek FWG, De Maat MPM, Rijken DC, Pereira AM, Romijn JA, Netea-Maier RT, Hermus AR, Zelissen PMJ, De Jong FH, Van der Lely AJ, De Herder WW, Lamberts SWJ, Hofland LJ, Feelders RA (2012) The hypercoagulable state in Cushing's disease is associated with increased levels of procoagulant factors and impaired fibrinolysis, but is not reversible after short-term biochemical remission induced by medical therapy. J Clin Endocrinol Metab 97:1303-1310
26. Kastelan D, Dusek T, Kraljevic I, Polasek O, Giljevic Z, Solak M, Salek SZ, Jelcic J, Korsic M (2009) Hypercoagulability in Cushing's Syndrome: the role of specific haemostatic and fibrinolytic markers. Endocrine 36:70-74
27. Mann KG, Butenas S, Brummel K (2003) The dynamics of thrombin formation. Arterioscl Thromb Vasc Biol 23:17-25
28. Smid M, Dielis AW, Winkens M, Spronk HM, Van Oerle R, Hamulyak K, Prins MH, Rosing J, Waltenberger JL, Ten Cate H (2011) Thrombin generation in patients with a first acute myocardial infarction. J Thromb Haemost 9:450-456
29. Vambergue A, Rugeri L, Gaveriaux V, Devos P, Martin A, Fermon C, Fontaine P, Jude B (2001) Factor VII, tissue factor pathway inhibitor, and monocyte tissue factor in diabetes mellitus: influence of type of diabetes, obesity index, and age. Thromb Res 101:367-375
30. Cvirn G, Gallistl S, Leschnik B, Muntean W (2003) Low tissue factor pathway inhibitor (TFPI) together with low antithrombin allows sufficient thrombin generation in neonates. J Thromb and Haemost 1:263-268
31. Boscaro M, Sonino N, Scarda A, Barzon L, Fallo F, Sartori MT, Patrassi GM, Girolami A (2002) Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing's Syndrome. J Clin Endocrinol Metab 87:3662-3666
32. Sauls DL, Banini AE, Boyd LC, Hoffman M (2007) Elevated prothrombin level and shortened clotting times in subjects with type 2 diabetes. J Thromb Haemost 5:638-639
33. Casonato A, Pontara E, Boscaro M, Sonino N, Sartorello F, Ferasin S, Girolami A (1999) Abnormalities in von Willebrand factor are also part of the prothrombotic state of Cushing's Syndrome. Blood Coagul Fibrinolysis 10:145-151
34. Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR (1995) Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 345:152-155
35. Cristina L, Benilde C, Michela C, Mirella F, Giuliana G, Gualtiero P (2004) High plasma levels of factor VIII and risk of recurrence of venous thromboembolism. Br J Haematol 124:504-510
36. Koutroumpi S, Daidone V, Sartori MT, Cattini MG, Albiger NM, Occhi G, Ferasin S, Frigo A, Mantero F, Casonato A, Scaroni C (2012) Venous thromboembolism in patients with Cushing's Syndrome: need of a careful investigation of the prothrombotic risk profile. Pituitary. doi: 10.1007/s11102-012-0398-4
37. Spronk HM, Dielis AW, De Smedt E, Van Oerle R, Fens D, Prins MH, Hamulyák K, Ten Cate H (2008) Assessment of thrombin generation II: validation of the Calibrated Automated Thrombogram in platelet-poor plasma in a clinical laboratory. Thromb Haemost 100(2):362-364
38. Castoldi E, Rosing J (2011) Thrombin generation tests. Thromb Res 127:S21-S25